ArticleCureus2025
MUC5B (rs35705950) Polymorphism and Its Association With Serum Krebs Von Den Lungen-6 (KL-6) and Matrix Metalloproteinase-7 (MMP7) in Patients With Interstitial Lung Disease (ILD) From India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose Krebs von den Lungen-6 (KL-6) and matrix metalloproteinase-7 (MMP7) are established serum biomarkers for interstitial lung disease (ILD). A combination of KL-6 and MMP7 may be a useful screening tool for patients at risk of ILD. However, data on their association with MUC5B promoter polymorphism (rs35705950) in Indian ILD patients are lacking. There is a gap in knowledge of MUC5B genotypes in different subtypes of ILD and the diagnostic cut-offs of serum KL-6 and MMP7 in ILD patients from India. The primary aims of this study were to evaluate the proportion of MUC5B promoter polymorphism in different subtypes of ILD and to establish diagnostic cut-offs for serum KL-6 and MMP7 to distinguish ILD patients from healthy controls. The secondary aim was to investigate whether there was any genotype-phenotype association between the MUC5B genotype and serum biomarker levels. Methods This cross-sectional study was conducted in 200 ILD patients from a tertiary care institute in India. Serum KL-6 and MMP7 levels were measured using ELISA. Genotyping for MUC5B (rs35705950) was performed using DNA extracted from peripheral blood leukocytes. Results Connective tissue disease-associated interstitial lung disease (CTD-ILD) was the most common ILD subtype (45%). KL-6 levels were higher in idiopathic pulmonary fibrosis (IPF) than fibrotic hypersensitivity pneumonitis (fHP) (105.6 ng/mL vs. 65.87 ng/mL; p=0.0409), in patients who died (109.8 ng/mL vs. 68.6 ng/mL; p=0.022), and in the MUC5B (rs35705950) GT/TT genotype (85.07 ng/mL vs. 65.58 ng/mL; p=0.019). MMP7 levels were higher in IPF than CTD-ILD and fHP (14.01 ng/mL vs. 8.690 ng/mL and 7.970 ng/mL; p=0.0175 and p=0.0118, respectively). The minor MUC5B T allele was more frequent in all ILD subtypes. Conclusion This study established an association between MUC5B (rs35705950) promoter polymorphism and higher serum KL-6 levels. The T minor allele had a higher frequency in all ILD subtypes. The study also established cut-offs of serum KL-6 and MMP7 to distinguish between Indian ILD patients and controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.